Descrizione business
Marinomed Biotech AG is a biopharmaceutical company with headquarters in Vienna and has been listed in the Prime Market of the Vienna Stock Exchange. The company focuses on the development of innovative products based on patent-protected technology platforms. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as eyes, nose, lung or gastrointestinal tract. The Carragelose® platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and can reduce the risk of an infection with SARS-CoV-2. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 30 countries worldwide.
Consiglio di amministrazione & Consiglio di sorveglianza
CEO |
Andreas Grassauer |
Consiglio di amministrazione |
Pascal Schmidt, Eva Prieschl-Grassauer |
Consiglio di sorveglianza |
Simon Nebel, Brigitte Ederer, Elisabeth Lackner, Ulrich Kinzel, Eva Hofstaedter-Thalmann |
Dati aziendali
Name: |
Marinomed Biotech AG |
Indirizzo: |
Hovengasse 25,A-2100 Korneuburg |
Telefono: |
+43-2262-90300 |
Fax: |
- |
E-mail: |
office@marinomed.com
|
Internet: |
https://www.marinomed.com/de/ |
Industria: |
Healthcare |
Settore: |
Pharmaceutical Industry |
Sub settore: |
Pharmaceuticals |
Fine dell'anno finanziario: |
31/12 |
Flottante libero: |
- |
Data dell'IPO: |
01/02/2019 |
Rapporti con gli investitori
Name: |
Stephanie Kniep |
IR telefono: |
- |
IR Fax: |
- |
IR e-mail: |
ir@marinomed.com
|